Monthly shot may beat daily pills for schizophrenia

NCT ID NCT07075237

Not yet recruiting Disease control Sponsor: Jiangsu Province Nanjing Brain Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether switching from daily oral antipsychotics to a monthly injection of paliperidone palmitate helps people with schizophrenia control symptoms and improve social function. Researchers will enroll 120 adults aged 18-65 who are stable on oral meds. Participants receive injections for 6 months, and the team tracks symptom severity and daily functioning.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: paliperidone palmitate injection
What this could lead to: If successful, this could show that switching to a monthly injection helps people with schizophrenia maintain symptom control and improve social functioning better than daily pills.
What could go wrong: This is a small, early-stage Phase 4 study with only 120 participants. Results may not apply to everyone, and injections can cause side effects like injection-site reactions or movement disorders.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia Social Adjustment

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA

Contacts and locations

Locations

Nanjing Brain Hospital

Nanjing, Jiangsu, 210024, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.